Business Wire

Knopp Biosciences Announces Election of Biotech Executive Shane Kovacs to Board of Managers


Knopp Biosciences LLC today announced the appointment of Shane Kovacs to its Board of Managers, effective immediately. Kovacs, a former life sciences investment banker, has served as Executive Vice President and Chief Financial Officer of PTC Therapeutics (NASDAQ: PTCT) since May 2013.

He joins the board of privately held Knopp as the company initiates advanced clinical development of dexpramipexole in hypereosinophilic syndromes (HES) and eosinophilic asthma. A pivotal trial in HES and a Phase 2 trial in eosinophilic asthma are planned to begin in the second half of 2017.

“Shane Kovacs brings outstanding corporate finance and general management experience to Knopp at a strategically important time for the company,” said Michael Bozik, M.D., president and CEO of Knopp. “We expect he will play an instrumental governance role in helping Knopp navigate our capital strategy, development planning, and potential commercialization activities.”

“I’m extremely excited to be joining Knopp at this critical point in the company’s evolution,” Mr. Kovacs said. “I have followed Knopp’s progress for several years and am enthusiastic about helping to guide the company through its next stage of corporate and clinical development.”

Prior to joining PTC in 2013, Mr. Kovacs served as Managing Director, Health Care Investment Banking at Credit Suisse, advising biotech companies on both financial and merger-and-acquisition transactions. He joined Credit Suisse in 2004 from an investment banking position at National Bank Financial in Toronto. He received an MBA from Richard Ivey School of Business at the University of Western Ontario and a Bachelors of Engineering in Chemical Engineering as well as a Bachelors of Sciences in Life Sciences from Queen's University in Kingston, Ontario. He is a CFA Charterholder.

Knopp’s Board of Managers is the LLC equivalent of a corporate board of directors.

Knopp’s lead product candidate, dexpramipexole, is an orally available investigational drug that has demonstrated significant eosinophil lowering potential across multiple clinical studies, including in a Phase 2 study in HES. Eosinophils are white blood cells associated with inflammation in numerous diseases.


Knopp Biosciences, based in Pittsburgh, PA, USA, is a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need in clearly defined patient populations. Our clinical-stage small molecule, dexpramipexole, will be entering late-stage clinical studies in hypereosinophilic syndromes and Phase 2 clinical studies in eosinophilic asthma. Our preclinical platform is directed to small molecule treatments for neonatal epileptic encephalopathy, a devastating brain disorder of infants caused by a rare mutation in the KCNQ2 gene. Please visit

This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs for dexpramipexole. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that dexpramipexole will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market the product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.

Contact information

Knopp Biosciences LLC
Tom Petzinger, +1-412-488-1776

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Advantis Medical Imaging Receives CE Mark for Brainance® MD, its Cloud-Based Neuroimaging Software.20.3.2018 11:00Pressemelding

Advantis Medical Imaging announces that it received CE Mark approval for Brainance ® MD, its Cloud-Based Neuroimaging software. This market approval allows Brainance ® MD to be used as part of the clinical workflow for the advanced processing of Brain MR images. This press release features multimedia. View the full release here: “We feel really excited to make this announcement. This is a significant milestone for our company and the fact that Brainance ® MD can now be integrated in the clinical processing workflow fulfills one of Advantis principal goals: to make state-of-the-art processing methodologies available for every doctor, anywhere, anytime. ” said Zoi Giavri, CEO and co-founder of Advantis Medical Imaging. “This CE Mark approval confirms our capacity for innovation and justifies the entire team’s devotion and effort on striving for increased quality and performance, while bringing added value to the daily clinical pra

Tan Delta: Not All Condition Based Monitoring is the Same.20.3.2018 10:35Pressemelding

Condition based monitoring (CBM) and maintenance programmes typically include many interrelated technologies. CBM provides an assessment of equipment condition, based on collecting and interpreting data with a view to providing maintenance at the optimum point. This allows a company to make cost-effective and logical maintenance decisions, reducing scheduled costs and reducing in-service fault repair costs, by eliminating run-to-failure and the associated consequences of unscheduled downtime. This press release features multimedia. View the full release here: Tan Delta: Not All Condition Based Monitoring is the Same. (Photo: Business Wire) Oil analysis is increasingly recognised as a critical element of condition based monitoring. Oil analysis provides important information about equipment wear-condition, as well as the condition of the oil itself. Keeping machinery operating at the optimal level involves measuring, monitoring a

Accudyne Industries Selects LTI as its IT Infrastructure & Security Management Partner20.3.2018 10:30Pressemelding

Larsen & Toubro Infotech Ltd. (NSE: LTI, BSE: 540005), a global technology consulting and digital solutions company, has been selected by Accudyne Industries, LLC (Accudyne Industries) as the transformation partner to provide IT Infrastructure & Security Management Services. Accudyne Industries is a leading global provider of precision engineered, process-critical and technologically advanced flow control systems and industrial compressors. Accudyne’s businesses support complex, large-scale installations within oil and gas, energy, petrochemical, chemical, industrial manufacturing, construction, mining, and water and wastewater treatment industries. Accudyne chose LTI as its consulting and IT services partner to enhance end-user experience while attaining flexibility and scalability across its business landscape. LTI will provide services leveraging an intelligent, global, managed services engagement model supported by a command and security operations center. Frank DeArmas, Chief Info

Favorable safety profile of Pradaxa® (dabigatran etexilate) confirmed in large prospective real-world analysis20.3.2018 10:09Pressemelding

New data from one of the largest prospective ongoing global studies examining the use of oral antithrombotics for stroke prevention in atrial fibrillation (AF) in clinical practice, GLORIATM-AF, were presented at the EHRA 2018, the annual congress of the European Heart Rhythm Association (EHRA).1,2 The registry examined two-year safety and effectiveness outcomes of nearly 5,000 AF patients treated with dabigatran (marketed as Pradaxa®). Results of the completed Phase II of GLORIATM-AF,1 presented during the ‘Late-breaking science – Registries’ session, showed low rates of major bleeding (0.97%) and stroke (0.65%). These findings confirm the sustained safety and effectiveness of dabigatran and are highly consistent with the long-term safety profile observed in other real-world evidence, as well as in randomised clinical trials. This press release features multimedia. View the full release here: “Long-term, ‘real-world’ data are i

IDEMIA: Easier Travel with the Biometric Innovations Presented at Passenger Terminal Expo (20–22 March 2018)20.3.2018 09:46Pressemelding

IDEMIA, the global leader in Augmented Identity, has announced his attendance to Passenger Terminal Expo (PTE) 2018, the world’s biggest aviation industry exhibition. Bringing together all industry stakeholders, including airlines, airport operators and public authorities, PTE begins today and will be held in Stockholm until March 22 nd . As passenger numbers in airports continue to soar1, the need to manage flows efficiently coupled with particularly rigorous screening procedures, is becoming more strategic than ever. With its innovative Augmented Identity, IDEMIA provides a smoother passenger experience based on identification whilst ensuring that security requirements are respected. In that context, IDEMIA today operates free-flow passenger solutions in several international airports through the world. For instance, Singapore Changi Airport, voted the world’s best airport for the fifth consecutive year, recently chose IDEMIA for the provision of biometric identification and authenti

ESSENZIALED Recessed & Linear Lamps Have Adopted Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs20.3.2018 08:07Pressemelding

Seoul Semiconductor, a global innovator of LED products and technology, announced that its SunLike Series natural spectrum LEDs, which implement light closest to the spectrum of natural sunlight, has been adopted for luminaires from ESSENZIALED, including the Spottone and Mood Series luminaires. This press release features multimedia. View the full release here: ESSENZIALED Mood-Round & Square spotlights with SunLike LEDs (Photo: Business Wire) Marino Bertazza, CEO and founder of ESSENZIALED, explained, “SunLike technology delivers a superior color rendering index, with a spectrum that closely matches that of natural sunlight. Our customers appreciate the quality of light and the visual comfort delivered by SunLike Series natural spectrum LEDs.” According to Caleb Won, executive VP of global marketing at Seoul Semiconductor, “ESSENZIALED’s choice of SunLike Series natural spectrum LEDs will achieve synergy effects and contribute